Long-term follow-up of patients receiving CAR-T cell therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study is designed to monitor patients who have received CAR-T cell therapy as part of various clinical trials at the Medical College of Wisconsin and Froedtert Hospital. Participants will be followed for a duration of 2 to 15 years to assess the persistence of CAR-T cells, the occurrence of secondary malignancies, and any other medical complications that may arise. The observational nature of the study allows for comprehensive data collection on long-term outcomes and safety profiles of CAR-T cell treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All participants who enrolled in a CAR-T study at Froedtert Hospital \& the Medical College of Wisconsin.

Exclusion Criteria:

* There are no exclusion criteria for this study.

Where it's running

• Froedtert Hospital & Medical College of Wisconsin
  Milwaukee, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Nirav Shah — Medical College of Wisconsin
• Study coordinator: Medical College of Wisconsin Clinical Cancer Center
• Email: cccto@mcw.edu
• Phone: 414-805-8900

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment

  This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT06784167

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Using LV20.19 CAR T-Cells with Pirtobrutinib for B-cell Malignancies

  This study is testing a new treatment combining LV20.19 CAR T-cells with pirtobrutinib to see if it helps adults with tough-to-treat B-cell cancers feel better.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05990465

• Local production of CAR T-cells for treating B-Cell cancers

  This study is testing whether making CAR T-cells locally can help patients with B-Cell lymphoma and leukemia have a safe and effective treatment.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT05281809

• Treatment for relapsed or refractory CD19+ lymphoid diseases using engineered T cells

  This study is testing a new treatment using specially modified immune cells to help adults and children with certain types of blood cancers that haven't responded to other therapies.

  Recruiting at 2 sites Phase 1/2 University Hospital Heidelberg · Heidelberg and 1 other locations · NCT03676504

• Hematopoietic stem cell transplant for blood cancers

  This study is testing two different ways of doing stem cell transplants for people with blood cancers to see which method works better and is safer.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03314974

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.